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Inflammatory bowel diseases (IBDs) are a group of chronic, relapsing, immune-mediated disorders of the intestine, including
Crohn’s disease and ulcerative colitis. Recent studies underscore the importance of the damaged epithelial barrier and the
dysregulated innate immune system in their pathogenesis. Metallothioneins (MTs) are a family of small proteins with a high and
conserved cysteine content that are rapidly upregulated in response to an inflammatory stimulus. Herein, we review the current
knowledge regarding the expression and potential role of MTs in IBD. MTs exert a central position in zinc homeostasis, modulate
the activation of the transcription factor nuclear factor (NF)-κB, and serve as antioxidants. In addition, MTs could be involved in
IBD through their antiapoptotic eﬀects or through specific immunomodulating extracellular eﬀects. Reports on MT expression in
IBD are contradictory but clearly demonstrate a deviant MT expression supporting the idea that these aberrations in IBD require
further clarification.
Copyright © 2009 Anouk Waeytens et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Metallothioneins (MTs) are a superfamily of small proteins
that are present in virtually every living organism [1].
A typical feature is their highly conserved number and
position of cysteine residues, enabling them to incorporate
monovalent and divalent metal atoms and to reduce reactive
oxygen and nitrogen species [2]. So far, 19 human isoforms
have been cloned, 11 of which are known to be functional
(i.e., MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M,
MT1X, MT2A, MT3, and MT4) [3]. The majority of these
genes cluster together on a single locus on chromosome
16 (16q13) [4]. Heterogeneity of isoforms results from
posttranslational modifications and/or variations in metal
composition [5]. The most widely expressed isoforms are
MT-1 and MT-2, and they are highly inducible [3]. On the
basal level, MT-2 appears to be expressed more than the MT-
1 isoforms. The MT-3 and MT-4 proteins are constitutively
expressed and are found mainly in the brain [6], kidney [7],
and reproductive organs [8] (MT-3) and in certain squamous
epithelia [9] (MT-4). Human MT isoforms are regulated
independently of each other and can be induced by metals,
stress hormones, cytokines, reactive oxygen species (ROS),
and chemicals [3]. In mice, the situation is more simple.
Only four functional murine MT genes are known (MT1,
MT2, MT3, and MT4), and the MT1 and MT2 isoforms are
coordinately regulated [5, 10].
2. MT Regulation in Inflammation
One of the most striking observations that link MTs
to inflammation is their rapid upregulation in response
to a variety of stresses including inflammation. Hepatic
expression of MTs is dramatically elevated in response
to bacterial infection, an eﬀect mediated by endotoxin
(lipopolysaccharide-LPS). This observation has lead to the
classification of MTs as acute phase proteins. LPS induction
of MT gene expression in mice occurred in each organ
examined (liver, kidney, pancreas, intestine, lung, heart,
brain, ovary, uterus, and spleen) [11]. This induction by
LPS was shown to be mediated by several proinflammatory
cytokines, including interleukin (IL)-1, IL-6, tumor necrosis
factor (TNF)-α, interferon (IFN)-γ [11], nitric oxide (NO)
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[12] as well as the stress hormones glucocorticoids [13].
These factors have been shown to be able to upregulate
MTs independently of LPS. They seem to act synergistically
and result in diﬀerent levels of MT expression, depending
on the tissue and the combination of factors [11, 14–16].
ROS generated during the inflammatory response may acti-
vate MT expression through multiple pathways, including
directly by stimulating an antioxidant response element and
specific metal response elements in the promoter region as
well as indirectly by events associated with second-messenger
protein kinase pathways [17, 18]. During radiation injury
to the small intestine, which implicates ROS and leads to
acute inflammation, metallothioneins were induced [19]. All
these data illustrate that MT regulation in inflammation is a
rapid but complex process with diﬀerent results in diﬀerent
tissues. One constant, however, is that MT induction by
inflammatory mediators seems to be conditional upon the
presence of zinc [5].
3. MT Functions Relevant in
Inflammation and Possibly in Inflammatory
Bowel Diseases (Figure 1)
The first function of MTs that was put forward as playing a
role in inflammation was their central position in zinc home-
ostasis, redistributing the intracellular zinc pool. In that way,
MTs can have two opposite roles: they can either increase
the intracellular zinc pool, thereby facilitating metabolic
processes during the acute phase response or sequester
zinc to allow maximal activity of enzymes which would be
otherwise inhibited by zinc [5]. Clarifying these postulations
is hampered by the immense number of enzymes that use
or are inhibited by zinc. Furthermore, the aﬃnity of MTs
for zinc probably diﬀers depending on the stimulus by
which MTs are induced. In an in vivo displacement assay
of cadmium (whose aﬃnity for MT is stronger than that
of zinc), it was shown that oxidative stress-induced MT
displaced zinc to cadmium, on the other hand, MT induced
by fasting stress or by restraint stress did not [20]. This study
did not make a distinction between diﬀerent MT isoforms,
although metal-binding capacities of isoforms can vary [21,
22], as can their gene-regulation [23, 24]. Conformational
changes of MT under certain stimuli might also explain the
observed influence on zinc aﬃnity. It has been shown that the
binding of ATP (which reflects the energy state of a cell) to
MT elicited conformational changes and altered zinc binding
in MT [25].
Zinc deficiency is a potential complication of Crohn’s
disease and may result from a variety of processes, includ-
ing reduced dietary intake, impaired absorption, increased
excretion, hypoalbuminemia, or an internal redistribution of
zinc [26, 27]. Although the consequences of this deficiency
on the pathogenesis of the disease are not clear [28], it
could be implicated through the involvement of zinc in
immune function, redox signalling, and wound healing [29–
32]. Zinc is crucial for the normal development and function
of cells mediating innate immunity, that is, neutrophils,
macrophages, and natural killer cells [33]. Phagocytosis,
intracellular killing, chemotaxis, and oxidative burst are all
negatively aﬀected by zinc deficiency. In Crohn’s disease,
a defective innate immune response is more and more
accepted as a pathogenic mechanism [34]. Zinc also has
antiinflammatory properties. An important target herein is
nuclear factor (NF)-κB, a transcription factor that has a
pivotal role in immune and inflammatory responses and as
such also in IBD. Eﬀects of zinc on NF-κB activity have
been attributed to its influence on the expression of the zinc-
finger protein A20 that sequesters NF-κB in the cytoplasm
and inhibits IL-1- and TNF-α-induced activation of NF-κB
[35]. In vitro, zinc enhances the upregulation of A-20, thus
decreasing NF-κB activation and leading to decreased gene
expression and generation of TNF-α, IL-1β, and IL-8 [36].
Taking these findings into account, a lack of intracellular zinc
ion bioavailability may hamper the inhibition of NF-κB, with
subsequent maintenance of chronic inflammation.
The gene expression of IL-2, IL-12, and IFN-γ (T helper
type 1 or Th1 cytokines) is zinc dependent, whereas T helper
type 2 (Th2) cytokines in general are not aﬀected by zinc
deficiency [33]. As a consequence, an imbalance of Th1/Th2
cytokines appears in an experimental model of human zinc
deficiency with a decrease of Th1 cytokines and a shift toward
a Th2 phenotype [37]. This observation stands in contrast
with the excessive Th1 cell response in the inflamed mucosa
of Crohn’s disease patients with active disease. However, in
Crohn’s disease patients with inactive disease, hyposecretion
of IFN-γ is reported [38, 39]. Even though a relationship
with zinc status has not been examined in these studies, zinc
deficiency could be at the basis of this observation.
Studies where zinc was administered to rats or mice
with chemically induced colitis showed a dose-dependent
therapeutic eﬀect [40–44]. Furthermore, zinc was shown
to induce MT synthesis in ileal and colonic mucosa of
control rats and to a lesser extent in that of colitic rats
[45]. A placebo-controlled double-blind cross-over trial was
conducted with seven Crohn’s disease patients and seven
ulcerative colitis patients that had inactive to moderately
active disease and received oral zinc supplementation [46].
Although supplementation increased plasma zinc concentra-
tions and slightly (but not significantly) increased mucosal
MT concentration, there were no changes in histological
inflammation or disease activity. However, it seems that
zinc supplementation can resolve permeability alterations
in patients with Crohn’s disease in remission and as such
reduce the risk of relapse in Crohn’s disease [47]. This
observation is supported by data that show a positive eﬀect of
exogenous zinc on intestinal repair in vitro [30] and on tight-
junction permeability in experimental colitis [42]. Although
the precise mechanism is not understood, it appears to be
independent of MTs [48].
Next to their role in zinc homeostasis, MTs are reported
to modulate the activation of NF-κB. However, published
results vary concerning the relationship between MT expres-
sion level and NF-κB activity. The modulatory eﬀect might
be based upon a direct interaction [49], regulation of zinc
concentrations [50], or modulation of the redox balance
through antioxidant functions [51]. Data supporting a pos-
itive regulatory role for MTs on NF-κB activity are the zinc-
induced inhibition of this activity. Through sequestration
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Figure 1: MT functions relevant in IBD. IBD is characterized by the presence of an increased level of ROS in the mucosal intestinal tissue as
well as oxidative DNA and protein damage, defective host-microbe interactions, immune cell infiltration, and a disturbed T cell apoptosis.
On all of these elements, MTs can have eﬀects. In addition, MTs can have a dual role in enzyme activation through the release or sequestration
of zinc. Finally, MTs are reported to regulate the activation of the transcription factor NF-κB, which has a key role in inflammatory responses.
of zinc, MTs can attenuate this zinc-induced inhibition
and activate NF-κB [50]. The requirement of MTs for
the expression of macrophage colony stimulating factor, a
chemokine downstream of NF-κB, is another illustration of
this positive regulatory role [52]. On the other hand, data
exist that MTs may function as a negative regulator of NF-κB,
showing that MTs inhibited the activation of NF-κB by TNF-
α [53, 54] and that splenocytes from MTnull mice displayed
elevated levels of NF-κB activity [55]. Although these reports
seem contradictory, explanations for this discrepancy could
be found in the distinct redox regulation of NF-κB activation
between the cytoplasm and the nucleus [51], a balance
which may be modulated by the antioxidant capacities of
MTs. Another explanation might be found in diﬀerences
in the cell types used. Although it seems obvious that a
(negative or positive) correlation exists, MT eﬀects can also
be independent of NF-κB. For example, a protective eﬀect of
MTs on acute inflammatory lung injury was not mediated
via NF-κB dependent pathways [56]. Thus, to determine
the exact role of MTs in the NF-κB pathway in IBD, NF-
κB activity should be investigated in vivo in experimental
models.
As just mentioned, the antioxidant capacities of MTs
might influence the inflammatory response through mod-
ulating NF-κB activity, but a more obvious role for MTs
as antioxidants is the sequestration of harmful oxygen
and nitrogen intermediates which are generated during
the inflammatory response. In order to kill bacteria and
parasites, infiltrating neutrophils and macrophages produce
free oxygen radicals (hydrogen peroxide, NO, and superoxide
anion) which are extremely cytotoxic to host cells [57, 58].
MTs can, together with other known molecules such as
superoxide dismutase, vitamin E, and ascorbate, provide a
cytoprotection for host cells, preventing cellular damage and
allowing survival and growth in an inflammatory environ-
ment [59]. The increased presence of ROS, an imbalance
in antioxidant expression, and oxidative DNA and protein
damage have been reported in IBD [60–63]. In Crohn’s
disease, oxidative damage as measured by lipid peroxidation
correlated inversely with the concentration of MTs [61]. ROS
can disrupt the epithelial barrier function by destabilizing
tight junctions [64], thus increasing permeability, a phe-
nomenon which is observed in patients with Crohn’s disease
[65]. Experiments in animal models of IBD have already
confirmed the possibility to use antioxidants as therapeutic
agents [66–69]. In IL-10 deficient mice, local mucosal
administration of the antioxidant enzyme superoxide dis-
mutase (SOD) by genetically modified Lactobacillus bacteria
significantly reduced the severity of inflammation [70].
Mice overexpressing human SOD demonstrated attenuated
inflammation when subjected to a mild form of dextran
sodium sulphate- (DSS-) induced colitis and a remarkable
survival benefit from severe DSS colitis [71].
In certain oxidative and inflammatory environments
MTs have been shown to reduce apoptosis [72], and in
cases where inflammation-dependent apoptosis is detri-
mental, induction of MTs might provide a benefit. Since
Crohn’s disease is characterized by defective T cell apoptosis,
whereas T cells from ulcerative colitis patients show a strong
activation induced apoptosis, the role of MTs might be
diﬀerent in these two diseases. MTs have also been accredited
antimicrobial properties [73, 74], which might be another
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relevant feature given the defective interaction of the host
with the mucosal flora in IBD. Macrophages isolated from
MTnull mice showed a significantly lower bactericidal eﬀect
on Staphylococcus aureus than macrophages from control
mice. Furthermore, LPS- and TNF-α-stimulated MT-null
macrophages produced less NO than those from control
mice, which was due to reduced activity of inducible NO
synthase [73]. One MT isoform that was isolated and
purified from housefly larvae had direct antibacterial eﬀects
on Escherichia coli as assayed by the plate growth inhibition
assay [74].
Under certain conditions such as cell proliferation,
diﬀerentiation, and after cell injury, MTs are translocated
from the cytosol to the nucleus. MT regulation during cell
cycle progression has been demonstrated in normally cycling
cells, with maximal nuclear accumulation within the S and
G2 phases. High cytoplasmic expression occurred during
late G1 and G1/S transition, and basal amounts were found
in the G0 phase [75, 76]. Hepatocytes show a transient
nuclear localization of MTs at the G1-to-S phase transition
during the priming phase of liver cell regeneration after
partial hepatectomy [77]. Two premises for the nuclear
retention of MTs have been proposed. First, it might reflect
the role of MTs as chaperones to provide zinc for crucial
enzymes and transcription factors involved in cell division
[78]. Otherwise, it has been proposed that it might protect
DNA from oxidative damage [79].
Beside their intracellular functions, MTs could also be
involved in inflammation and IBD through specific extra-
cellular eﬀects [80]. For example, MTs have been shown to
directly and specifically mediate leukocyte chemotaxis [81].
Extracellular MTs can stimulate lymphocyte proliferation
[82]. MT binds to the plasma membrane of both T and B
lymphocytes, but, in the absence of a costimulatory agent,
MT induces lymphoproliferation only in B cells. MT also
enhances the capacity of naive B lymphocytes to diﬀerentiate
into plasma cells [83]. On the other hand, MTs can suppress
cytotoxic T cell function in vitro and a T-dependent humoral
response in vivo [84–86].
4. MT Expression in IBD
Given their possible functions in IBD pathogenesis, the
expression of MTs has been studied in patient samples
by diﬀerent research groups. These studies have yielded
contradictory results (Table 1) and as such the role of
MTs in IBD is not yet clarified. First of all, two studies
reported an increase in MT expression in IBD [87, 88], while
the rest demonstrated a downregulation. In most studies
no diﬀerences were reported between Crohn’s disease and
ulcerative colitis, except in two studies (both using DNA
microarrays) where opposite findings were found, that is,
decreased MT expression in ulcerative colitis and normal
expression in Crohn’s disease [89] versus normal expression
in ulcerative colitis and increased MT expression in Crohn’s
disease [88]. The influence of medication is also not clear yet,
given that one study reports an influence of steroid therapy
on MT expression [90] whereas a second study contests this
[91]. A study describing downregulation of MTs in vitro in
colon epithelial cells after stimulation with azathioprine did
not discuss this eﬀect in patients, although two azathioprine-
treated patients were included in the study [88]. The results
of this study should be interpreted cautiously, considering
the small dataset used. Finally, the immunohistochemical
studies do not agree whether MT expression is confined
to the epithelium [92–94] or whether expression in the
lamina propria occurs as well [87, 90, 91]. The study of
MT protein expression in IBD is even complicated by the
possible destructive influence of the oxidative environment
on the immunodominant epitope of the protein. Therefore,
it is not sure whether the absence of immunoreactivity equals
absence of MT protein or whether it reflects a failure of the
antibody to recognize the present protein.
The inconsistencies between the various studies could
be explained by diﬀerent sampling. MT expression could
depend on the grade of local inflammation but also on
the intestinal region, that is, ileum versus colon. Therefore,
an ileal sample that has signs of mild inflammation and a
piece of colonic tissue that suﬀers severe inflammation, both
from a Crohn’s disease patient, may possibly show diﬀerent
MT expression levels, although they will both be considered
“Crohn’s disease” samples. Therefore, careful sampling and
precise classification of the samples could help in elucidating
the exact MT expression pattern in IBD. Furthermore,
patient characteristics such as age, medication, disease activ-
ity, zinc status, or even food intake before sampling could
also influence MT levels and should therefore, if possible, be
examined or at least mentioned in the study outline.
5. MTs in Experimental Colitis Models
The availability of MTnull mice (knockout for MT1 and
MT2) and the use of recombinant MT have permitted the
investigation of the involvement of MTs in animal models
of inflammation. In the DSS model of colitis, MTs were
not protective in two separate studies comparing MTnull
mice with wild type mice [44, 94]. One of these studies
even found that, after DSS administration, MTnull mice had
a significantly lower disease activity index than had wild
type mice [44], suggesting that MTs are rather unfavorable
in DSS colitis. This finding was, however, not confirmed
on histology. In disagreement with this postulation is the
observation that, in the same study, administration of zinc
as an MT-inducer resulted in a lower disease activity index
and less histological damage. Nevertheless, it could not be
proven that this eﬀect was MT-dependent since no increase
in colonic MT-levels was found following zinc-treatment.
The second study did not provide disease activity indices
and found no diﬀerences in histological colon damage
between MTnull mice, wild type mice, and transgenic mice
overexpressing MT1 in the intestine [94]. This study found a
fourfold increase in total colon MT concentration after seven
days of DSS administration, diﬀerent from other studies in
experimental colitis that found no changes [44] or a decrease
in MT content [45] in DSS mice or in dinitrobenzene-
sulphonic acid colitic rats, respectively. Apparently, the
behaviour of MTs in experimental colitis models is as obscure
as in human IBD.
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Table 1: MT expression in IBD patients. CD: Crohn’s disease, UC: ulcerative colitis, IHC: immunohistochemistry, RIA: radio-immunoassay,
Ag-hem: Silver-heme saturation assay, and qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction.
Study Subjects Methods Results
Clarkson et al. [90]
Ileal resection specimens of 13 CD
patients (6 had received steroid
therapy; 5 had not), 2 UC patients,
and 3 controls
IHC on resection
specimens
Less MT immunoreactivity in patients with
IBD than controls; patients on steroid therapy
had more immunoreactivity;
immunoreactivity in enterocytes and lamina
propria
Elmes et al. [91]
Ileal resection specimens of 17 CD
patients (11 had received steroid
therapy; 6 had not), and 5 controls
IHC on resection
specimens
Decreased intestinal MT in IBD patients; no
significant diﬀerence when patients had
received steroid therapy; immunoreactivity in
enterocytes and basement membrane region
Mulder et al. [95]
19 ileum and 16 colon specimens
from 29 CD patients; 12 colon
specimens and 1 ileum specimen
from 12 UC patients; colon
specimens from 18 control patients
RIA on homogenized
mucosa (dissected
from resection
specimens)
MT content was decreased in noninflamed IBD
mucosa compared with control mucosa;
further decrease, was found in inflamed
mucosa; no diﬀerences between UC and CD;
no significant eﬀect of medication or tissue
localization
Sturniolo et al. [96] Colonic biopsies of 24 UC patients
and 10 controls
Ag-hem on biopsies
Reduced MT concentrations in patients with
active disease as compared with controls and
patients in remission; reduced MT
concentrations in inflamed versus noninflamed
mucosa taken from the same patient
Bruwer et al. [87] 22 CD patients, 48 UC patients, 10
controls
IHC on resection
specimens
MT overexpression in the fibroblasts of all
ulcerative and/or fissural lesions in UC and
CD; MT overexpression in intestinal epithelial
cells of 40% of UC and CD lesions correlated
significantly with the grade of inflammation
Lawrance et al. [89]
Colonic resection specimens with
moderately severe histological
inflammation from 12 UC and 6
CD patients (with moderately
severe clinical disease) and from 6
controls
DNA microarray
Decrease of MT1H and MT1G mRNA
expression in UC; no diﬀerence in CD
Ioachim et al. [92]
Ileum, colon or rectum resection
specimens from 10 CD patients, 41
UC patients, 5 controls
IHC
Decreased MT expression in UC and CD
compared with normal mucosa; no diﬀerence
in MT expression between UC and CD; in UC,
a gradually decreased expression from
remission, to resolving and to active phase was
observed; only epithelial MT expression
Kruidenier et al. [93] Resection specimens from 19 CD
patients, 15 UC patients, 18 controls
RIA on tissue
homogenates and IHC
on resection specimens
RIA: Lower tissue MT content in inflamed CD
and UC mucosa compared with noninflamed
and control mucosa; IHC: decreased
MT-positive epithelial cell numbers at
inflamed sites in CD and UC patients; no
detection of MT in lamina propria
Dooley et al. [88]
2 sets of colon samples: (a) control
(1 uninvolved colon from CD
patient), 1 CD patient, and 1 UC
patient; (b) control, 1
azathioprine-treated CD patient,
and 1 azathioprine-treated UC
patient; drug-treated CaCo-2 cells
microarray and
qRT-PCR with
consensus primer
sequences for multiple
metallothionein genes.
Microarray: upregulation of MT1F, MT1G,
MT1H in CD in tissue set (a); downregulation
of MT1F, MT1H, MT1L in
azathioprine-treated CaCo-2 cells; confirmed
by qRT-PCR
6. Protective Functions of MTs in
Other Animal Models of Inflammation
The role of MTs in models of other inflammatory conditions
seems clearer and in most cases is a favorable one. In an
animal model for multiple sclerosis, a chronic inflammatory
and demyelinating disease of the central nervous system in
which oxidative stress plays a pathogenic role, MTs were
demonstrated to be protective [97]. MTnull mice were
more susceptible to Helicobacter pylori-induced gastritis and
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showed more severe inflammation of the stomach than wild
type mice [98]. This correlates with the reported antibacterial
activity that was associated with MT function. This activity
might be mediated directly by MTs themselves [74] or
indirectly through nitric oxide production [73]. Endogenous
MT protected against acute lung injury induced by LPS,
especially against pulmonary oedema [56]. In the collagen-
induced arthritis model, repeated administration of MT1
and 2 during the course of disease dramatically reduced the
incidence and severity of the disease [99]. MTs suppressed
the disease through the generation of IL-10- and transform-
ing growth factor (TGF)-β-producing type 1 regulatory T-
like cells [100]. In all of these models, MTs seem to be
protective against local inflammation. In the TNF-induced
lethal shock model (a model for systemic inflammatory
response syndrome), however, MTs seem to sensitize [101].
An explanation for this finding was not found, although it
is contradictory to the reported resistance that MTs confer
to the cytotoxic eﬀects of TNF in vitro [102] and to the
protective eﬀects of MTs in another model of systemic
inflammatory response syndrome (LPS-induced lethal shock
in sensitized mice) [103]. The antiinflammatory eﬀects of
MTs on the LPS-related organ damages could be mediated,
at least in part, via the inhibition of the protein expression
of proinflammatory cytokines (IL-1β, IL-6) and chemokines
(granulocyte/macrophage colony-stimulating factor (GM-
CSF), macrophage inflammatory protein (MIP)-1α, MIP-
2, macrophage chemoattractant protein (MCP)-1, and ker-
atinocyte chemoattractant (KC)) [104].
7. Conclusion
Although several functional associations of MTs can confer
a role for this family of proteins in the pathogenesis of
IBD, the results of human and experimental colitis studies
are not decisive. However, it is clear that a deviant MT
expression exists in this disease, and as such it is important
to meticulously clarify these aberrations in Crohn’s disease
and in ulcerative colitis. Furthermore, investigating whether
the regulation of MTs in these diseases is dependent or
independent on inflammation will add knowledge on their
involvement in IBD.
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